FOR IMMEDIATE RELEASE
MESA, Ariz. — November 22, 2023
New today in Healthline is a summary of ACOG’s latest recommendations for the treatment of PMS and PMDD. These are two serious conditions affecting the lives of many women in the United States, are are often underdiagnosed. This article features the expert opinions of Dr. Greg Marchand. You can read the full article on Healthline’s website at: https://www.healthline.com/health-news/new-guidelines-for-severe-pms-pmdd-advise-antidepressants-cbt-and-birth-control
About the Marchand Institute for Minimally Invasive Surgery
The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised using the Cochrane RoB 2 tool. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS.
Media Contact
Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com | (480) 999-0905
Interview requests, expert commentary topics, boilerplate and high-resolution images: Newsroom & Press Kit. Complete publication record with DOIs and PMIDs: Publications database. Methodology: How we run a review.
###